Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Integra Lifesciences Holdings Corp
NASDAQ:IART
|
US |
|
Sparebanken Vest
OSE:SVEG
|
NO |
|
V
|
VINX Corp
TSE:3784
|
JP |
Paradigm Biopharmaceuticals Ltd
Total Equity
Paradigm Biopharmaceuticals Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Total Equity
AU$6m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$574.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Equity
AU$23.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Total Equity?
Total Equity
6m
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's Total Equity amounts to 6m AUD.
What is Paradigm Biopharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
-42%
Over the last year, the Total Equity growth was -82%. The average annual Total Equity growth rates for Paradigm Biopharmaceuticals Ltd have been -57% over the past three years , -42% over the past five years .
